Trial Profile
Phase I/II Evaluation of Oral Estramustine and Oral Vinorelbine on an Intermittent Schedule in Patients With Hormone-Refractory Adenocarcinoma of the Prostate
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Sep 2023
Price :
$35
*
At a glance
- Drugs Estramustine (Primary) ; Vinorelbine (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 20 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Jun 2009 New trial record.